br Clinical Practice Points br Most

Clinical Practice Points
· Most current research has explored racial disparities in lymphoma at a national level. This study sought to identify and describe racial disparities in non-Hodgkin lymphoma in a specific catchment area where its findings could be used to implement new clinical practices aimed at addressing these 4μ8C disparities.
ACCEPTED MANUSCRIPT
· Black patients in Georgia with DLBCL were more likely than Whites to present with stage III/IV disease and B symptoms and had significantly worse 2-year and 5-year relative survival.
· Regional information on racial differences in lymphoma incidence and presentation can help to inform future clinical practices directed at improving outcomes in poor-risk populations.
ACCEPTED MANUSCRIPT
References 1.– Siegel–RL,–Miller–KD,–Jemal–A.–Cancer–statistics,–2019.–CA–Cancer–J–
US–lymphoid–malignancy–statistics–by–World–Health–Organization–subtypes.–CA–
3.– Flowers–CR,–Fedewa–SA,–Chen–AY,–et–al.–Disparities–in–the–early–adoption–
of–chemoimmunotherapy–for–diffuse–large–B-cell–lymphoma–in–the–United–States.–
4.– Flowers–CR,–Nastoupil–LJ.–Socioeconomic–disparities–in–lymphoma.–Blood.–
Disparities–in–survival–by–insurance–status–in–follicular–lymphoma.–Blood.–
6.– Keegan–THM,–Li–Q,–Steele–A,–et–al.–Sociodemographic–disparities–in–the–
occurrence–of–medical–conditions–among–adolescent–and–young–adult–Hodgkin–
7.– Nabhan–C,–Byrtek–M,–Taylor–MD,–et–al.–Racial–differences–in–presentation–
and–management–of–follicular–non-Hodgkin–lymphoma–in–the–United–States:–report–
8.– Ritter–AJ,–Goldstein–JS,–Ayers–AA,–Flowers–CR.–Rural–and–urban–patients–
with–diffuse–large–B-cell–and–follicular–lymphoma–experience–reduced–overall–
9.– Shenoy–PJ,–Malik–N,–Nooka–A,–et–al.–Racial–differences–in–the–
presentation–and–outcomes–of–diffuse–large–B-cell–lymphoma–in–the–United–
presentation–and–outcomes–of–chronic–lymphocytic–leukemia–and–variants–in–the–
11.– Caglayan–C,–Terawaki–H,–Ayer–T,–et–al.–Assessing–the–Effectiveness–of–
Treatment–Sequences–for–Older–Patients–With–High-risk–Follicular–Lymphoma–With–
a–Multistate–Model.–Clin–Lymphoma–Myeloma–Leuk.–2019.–
12.– Chen–Q,–Ayer–T,–Nastoupil–LJ,–et–al.–Population-specific–prognostic–
models–are–needed–to–stratify–outcomes–for–African-Americans–with–diffuse–
13.– Flowers–CR,–Glover–R,–Lonial–S,–Brawley–OW.–Racial–differences–in–the–
incidence–and–outcomes–for–patients–with–hematological–malignancies.–Curr–
14.– Bulka–C,–Nastoupil–LJ,–McClellan–W,–et–al.–Residence–proximity–to–
benzene–release–sites–is–associated–with–increased–incidence–of–non-Hodgkin–
ACCEPTED MANUSCRIPT
16.– Howlader–N,–Noone–A,–Krapcho–M,–et–al.–SEER–cancer–statistics–review,–
17.– radiometric time Surveillance–E,–and–End–Results–(SEER)–Program.–SEER*Stat–Database:–
Incidence–-–SEER–18–Regs–Research–Data–+–Hurricane–Katrina–Impacted–Louisiana–
18.– Switchenko–JM,–Bulka–C,–Ward–K,–et–al.–Resolving–uncertainty–in–the–
spatial–relationships–between–passive–benzene–exposure–and–risk–of–non-Hodgkin–
19.– Bulka–C,–Nastoupil–LJ,–Koff–JL,–et–al.–Relations–Between–Residential–
Proximity–to–EPA-Designated–Toxic–Release–Sites–and–Diffuse–Large–B-Cell–
20.– Lee–JS,–Bracci–PM,–Holly–EA.–Non-Hodgkin–lymphoma–in–women:–reproductive–
Lymphoma–incidence–patterns–by–WHO–subtype–in–the–United–States,–1992-2001.–
22.– Monnereau–A,–Slager–SL,–Hughes–AM,–et–al.–Medical–history,–lifestyle,–
and–occupational–risk–factors–for–hairy–cell–leukemia:–the–InterLymph–Non-
Hodgkin–Lymphoma–Subtypes–Project.–J–Natl–Cancer–Inst–Monogr.–
23.– Morton–LM,–Slager–SL,–Cerhan–JR,–et–al.–Etiologic–heterogeneity–among–
non-Hodgkin–lymphoma–subtypes:–the–InterLymph–Non-Hodgkin–Lymphoma–Subtypes–
24.– Horesh–N,–Horowitz–NA.–Does–gender–matter–in–non-hodgkin–lymphoma?–
Differences–in–epidemiology,–clinical–behavior,–and–therapy.–Rambam–Maimonides–